NCT00869791: A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa |
|
|
| Completed | 2 | 27 | US | IPX066, ER CD-LD, IR CD-LD, immediate-release carbidopa-levodopa | Impax Laboratories, LLC | Parkinson's Disease | 06/09 | 06/09 | | |
NCT02271503: A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease |
|
|
| Completed | 2 | 26 | US | CD-LD IR, Sinemet, IPX203 180 mg, CD-LD ER 180 mg, IPX203 270 mg, CD-LD ER 270 mg, Rytary 195 mg, Rytary 145 mg | Impax Laboratories, LLC | Parkinson's Disease | 08/16 | 08/16 | | |
NCT05087914: Novel Non-opioid Post-surgical Pain Treatment in Females |
|
|
| Withdrawn | 2 | 60 | US | Carbidopa-Levodopa (100mg/25mg):, Sinemet, Parcopa, Rytary, Naproxen, Aleve, Anaprox, Naprosyn, Naprelan, Menstridol | Northwestern University, Northwestern Medical Group, National Institutes of Health (NIH) | Acute Pain, Bunionectomy, Toe Fusion | 12/23 | 01/24 | | |
